Medicines

Medical News Today: Do past medicines hold the answer to antibiotic resistance?

As the effectiveness of antibiotics wanes, scientists are looking at medications that preceded them, such as those involving metals and metalloids. Source link

Read more
Accelerating Medicines Partnership launches data knowledge portal for Parkinson’s disease

The Accelerating Medicines Partnership (AMP) program for Parkinson’s disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to develop effective...

Read more
STAT Plus: Pharmalittle: Novartis to pay $9.7 billion for The Medicines Co.; Trump bashes Pelosi drug pricing bill

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-so-familiar routine of meetings, Skype calls, and endless texting has...

Read more
The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $MDCO--The Medicines Company (NASDAQ: MDCO) announced today that it has entered into definitive agreement in which Novartis AG will acquire The Medicines Company for $85 per share...

Read more
Accelerating Medicines Partnership program for Parkinson’s disease launches new data portal

The Accelerating Medicines Partnership program for Parkinson's disease (PD) has launched a data portal to provide de-identified information collected from 4,298 PD patients and healthy controls to researchers working to...

Read more
The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing

PHILADELPHIA--(BUSINESS WIRE)---- $MDCO #ASCVD--The Medicines Company (NASDAQ: MDCO) today announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol (LDL-C) lowering Phase 3 clinical studies of...

Read more
Novartis announces strategy to broaden patient reach and availability of medicines in sub-Saharan Africa

Novartis announced today a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa, which is home to the largest underserved patient population in...

Read more
Essential medicines for patients with multiple sclerosis

In December 2018 MSIF submitted an application to the World Health Organization, to add MS treatments to the Essential Medicines List.   Source link

Read more
Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016–2017 epidemic season: a systematic review of seven Italian reports

The only pharmacologic prophylaxis against respiratory syncytial virus (RSV) infection in preterm infants is the humanized monoclonal antibody palivizumab. After the 2014 modification of the American Academy o... Source link

Read more
Opinion: Digital endpoints library can aid clinical trials for new medicines

At nearly every major industry conference — from HLTH to CNS Summit, Exponential Medicine, and Rock Health Summit — speakers are talking about the benefits of decentralized clinical trials and digital...

Read more
Herbal components of Japanese Kampo medicines exert laxative actions in colonic epithelium cells via activation of BK and CFTR channels

Herbal components of Japanese Kampo medicines exert laxative actions in colonic epithelium cells via activation of BK and CFTR channels Source link

Read more
After years of battling, Vertex and the U.K. reach a deal for cystic fibrosis medicines

After years of frustration, Vertex Pharmaceuticals struck a deal with the U.K. government to supply its cystic fibrosis medicines, capping an end to a dispute that had become a symbol...

Read more
 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia

LONDON--(BUSINESS WIRE)--Vertex announced reimbursement of SYMDEKO for eligible patients ages 12 and older, and ORKAMBI for children ages 2 to 5 in Australia. Source link

Read more
European Medicines Agency recommends licensing Ebola vaccine

The European Medicines Agency has recommended that the world's first Ebola vaccine be approved, after it was administered to hundreds of thousands of people in Africa. Source link

Read more
STAT Plus: Most state Medicaid programs continue to restrict access to hepatitis C medicines

Despite guidance from the federal government, most state Medicaid programs continue to deny hepatitis C treatments to beneficiaries, although more states are gradually easing restrictions, according to a new analysis....

Read more
Hepatitis Centres swept clean of medicines

KARACHI: The Hepatitis Centers run by the Hepatitis Prevention & Control Program Sindh across Sindh have been facing a grave shortage of Hepatitis C medication for the past several months...

Read more
Threat of Brexit-inspired medicines shortages dismissed

No medicines shortages anticipated by Medicines for Ireland even in no-deal Brexit scenario This story continues at Threat of Brexit-inspired medicines shortages dismissed Or just read more coverage at Irish...

Read more
STAT Plus: Sun Pharma shipped medicines into Alabama for two years without a permit

The Alabama Board of Pharmacy is weighing whether to renew a permit for Sun Pharmaceuticals (SUNPHARMA) to distribute its medicines in the state after discovering the company was shipping products...

Read more
A History of the US Medical Cannabis Movement and Its Importance to Pediatricians: Science Versus Politics in Medicine’s Greatest Catch-22

Clinical Pediatrics, Ahead of Print. Source link

Read more
STAT Plus: Vertex strikes a deal with Scotland for its cystic fibrosis medicines, but will England be next?

After protracted haggling, Vertex Pharmaceuticals struck a five-year deal with the Scottish government to provide its cystic fibrosis treatments at a “confidential discount,” a notable win for the drug maker...

Read more